Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.52 |
| ▸ | HTR3A | P46098 | 3/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062005 | 0.80 | ALDH1A1 (0.54) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL4207670 | 0.79 | CHRNA7 (0.61) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL4207672 | 0.79 | CHRNA7 (0.61) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7060957 | 0.78 | ALDH1A1 (0.70) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7128710 | 0.78 | ALDH1A1 (0.73) | ALDH1A1POLBCHRNA7HTR3A | |
| Hydrochloric Acid SCHEMBL4221906 | 0.78 | CHRNA7 (0.60) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| Hydrochloric Acid SCHEMBL4221903 | 0.78 | CHRNA7 (0.60) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL4198172 | 0.77 | ALDH1A1 (0.72) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL7059501 | 0.77 | ALDH1A1 (0.69) | ALDH1A1POLBCHRNA7HTR3AHTR3E | |
| SCHEMBL4202120 | 0.77 | ALDH1A1 (0.72) | ALDH1A1POLBCHRNA7HTR3AHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | ALDH1A1 267/4885POLB 344/4885CHRNA7 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.